The company is a specialty chemicals manufacturer based in Solapur, Maharashtra. The company manufactures aliphatic amines, derivatives, specialty chemicals and pharmaceutical excipients, with its products finding applications across pharmaceutical, agrochemical and other industrial sectors.
The shares of Balaji Amines are currently trading at Rs. 2,221.90, down by 0.18%. The company has a market capitalization of Rs. 7,193.02 crore. The stock’s 52 week high is Rs. 2,629.80 and its 52 week low is Rs. 968.10. In the past 6 months the stock has delivered a return of 109.53%.
What’s The News
Balaji Amines Limited has commenced commercial production at its Acetonitrile (ACN) plant with effect from September 24, 2026. The facility is located at Unit-III, Plot No. E-7 & E-8, Chincholi MIDC, Solapur, Maharashtra.
The commissioning follows the company’s expansion and modernisation programme and involves an upgraded ACN manufacturing facility using advanced technology. Following the expansion, the plant’s installed capacity has increased to 1,440 tonnes per month.
Capacity Expansion
Production of Acetonitrile (ACN) on commercial scale has started by Balaji Amines Ltd at their upgraded plant situated at Unit-III, Chincholi MIDC, Solapur, Maharashtra from September 24, 2026. With the completion of upgrade and modernization project, the total installed capacity of ACN production by the company has risen to 1,440 TPM.
Acetonitrile is a specialty chemical used across various industrial applications, including pharmaceuticals, chemicals and other downstream industries. The increased capacity is expected to strengthen Balaji Amines’ production capabilities and enable the company to cater to demand from both domestic and international markets.
The company had earlier disclosed that its improved-process ACN plant was under execution and was expected to be commissioned during Q2 FY27. With commercial production now commencing, the company has achieved this planned operational milestone and can progressively ramp up production from the expanded facility.
Financial performance
Looking at the quarterly results of Balaji Amines Limited, the company’s consolidated revenue from operations increased by 27.23 percent YoY, from Rs. 358.34 crore in Q1 FY26 to Rs. 455.92 crore in Q1 FY27, and grew by 15.49 percent QoQ from Rs. 394.78 crore in Q4 FY26. The company’s total revenue stood at Rs. 461.44 crore in Q1 FY27, compared with Rs. 367.36 crore in Q1 FY26 and Rs. 402.51 crore in Q4 FY26.
In Q1 FY27, Balaji Amines’ consolidated net profit increased by 113.79 percent YoY, reaching Rs. 78.12 crore, compared with Rs. 36.54 crore during the same period last year. As compared to Q4 FY26, the net profit increased by 20.61 percent, from Rs. 64.77 crore. The company’s EBITDA, excluding other income, stood at Rs. 115.87 crore, compared with Rs. 54.69 crore in Q1 FY26 and Rs. 94.24 crore in Q4 FY26, while the EBITDA margin improved to 25.41 percent from 15.26 percent in Q1 FY26.
The basic earnings per share increased by 97.19 percent YoY and stood at Rs. 23.13 in Q1 FY27, as against Rs. 11.73 recorded in Q1 FY26. On a sequential basis, EPS increased from Rs. 19.99 in Q4 FY26 to Rs. 23.13 in Q1 FY27.
Investor Perspective
The commencement of commercial production at the expanded ACN facility is an operational milestone for Balaji Amines, as the company now has an installed ACN capacity of 1,440 TPM. The key factors to monitor going forward will be the ramp-up of the expanded capacity, utilisation levels, realisations, demand from end-user industries and the contribution of ACN to overall revenue and profitability.
The development also adds to Balaji Amines’ specialty chemicals capacity at a time when the company is progressing with other projects. However, the financial benefit from the expanded ACN capacity will depend on actual production, utilisation and market conditions rather than installed capacity alone.